Mr. Andrew P. Witty is a Chief Executive Officer at InGensa, Inc., a Group President at UnitedHealth Group, Inc., a Chancellor at The University of Nottingham, a Chief Executive Officer at GlaxoSmithKline, Inc., a Chief Executive Officer & Director at GlaxoSmithKline Australia Pty Ltd. and a Member at Business Council for Britain.
He is on the Board of Directors at Synthego Corp., G1 Therapeutics, Inc., GlaxoSmithKline Australia Pty Ltd. and Pharmaceutical Research & Manufacturers of America. Mr. Witty was previously employed as a Lead Non-Executive Director by United Kingdom Department for Business, Innovation & Skills, a Chairman by European Federation of Pharmaceutical Industries & Assns, a Chief Executive Officer & Executive Director by GlaxoSmithKline Plc, a Chief Executive Officer & Director by Genelabs Technologies, Inc., a Director-Pharmacy & Distribution by Glaxo Holdings Plc, a Director-Business Development by Biocompatibles International Ltd., an Area Director by Glaxo Wellcome South Africa Pty Ltd., a Vice President & General Manager-Marketing by Glaxo Wellcome, Inc., a Senior Vice President-Asia Pacific by GlaxoSmithKline Pte Ltd., a Managing Director by GlaxoSmithKline South Africa, and a Member-International Advisory Council by Singapore Economic Development Board.
He also served on the board at INSEAD, Oxford Nanoimaging Ltd. and Singapore Land Authority.
He received his undergraduate degree from The University of Nottingham.